Clinical Trial Detail

NCT ID NCT03233347
Title Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Academic and Community Cancer Research United
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine

Age Groups: adult

No variant requirements are available.